glp-1 obesity drug news updates Upcoming wave of hormone-based therapies set to change field of diabetes, care Alarming rise in weight loss

The clinical results so far are hard to ignore

Mounjaro is dual-acting, while Ozempic affects one gut hormone.

GLP-1 Receptor Agonist Market size is growing with a CAGR of 12.5% in the prediction period and it crosses USD 72.33 Bn by 2033 from USD 31.71 Bn in 2026.

Looking for Tirzepatide or Semaglutide near you

Berbevis Berberine Phytosome, a highly absorbable form of berberine, helps with fat loss and to balance blood sugar

Currently, the Food and Drug Administration (FDA) has approved seven GLP-1 prescription medications:GENERIC NAMEBRAND NAMEFORMSSemaglutideOzempicRybelsusWegovyInjectionOral PillTirzepatideMounjaroZepboundInjectionLiraglutideVictozaSaxendaInjectionDulaglutideTrulicityInjectionExenatideByettaInjectionLixisenatideAdlyxinInjectionOrforglipron*Foundayo*Oral Pill*Non-peptide, small molecule When used in addition to a reduced calorie diet and increased physical activity, these medications are FDA approved for one or more of the following:Improving blood sugar levels in adults with T2D.Reducing excess body weight and keep it off long term in:Adults and children aged 12 years and older with obesity.Adults who are overweight who also have at least one weight-related medical problem (such as high blood pressure, diabetes, or high cholesterol)Reducing the risk of major adverse cardiovascular events in adults with T2D who have heart disease or are at high risk for these events.Can Service Members use GLP-1 prescription medications?GLP-1 medications are only available with a prescription from a qualified healthcare provider